Press releases

Top winners will be awarded up to $50,000 of in-kind support to advance submitted concept

Boston Scientific will participate in the healthcare investor conference on March 7, 2017. A live webcast and replay will be available.

Boston Scientific will participate in the healthcare investor conference on Feb. 23, 2017. A live webcast and replay will be available.

"Boston Scientific delivered excellent financial results in 2016,” said CEO Mike Mahoney

Boston Scientific will participate in the healthcare investor conference on Feb. 15, 2017. A live webcast and replay will be available.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 ended Dec. 31, 2016. Learn how to tune in.

Boston Scientific will participate in the J.P. Morgan Healthcare Conference on January 10, 2017. A live webcast and replay will be available.

Acquisition will bring manufacturing assets and biologic tissue capabilities for use in Boston Scientific heart valve technologies.

Third consecutive “Best Places to Work for LGBT Equality” award

$75M transaction enhances manufacturing expertise in structural heart

Boston Scientific will participate in the healthcare conference on December 7, 2016. A live webcast and replay will be available.

Acquisition expands Boston Scientific endoscopy portfolio with a comprehensive array of gastrointestinal services and devices

Boston Scientific today announced that its Cork, Ireland manufacturing facility has received the 2016 Shingo Prize for Excellence in Manufacturing from the Shingo Institute, part of the Jon M....

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 28th Annual Piper Jaffray Healthcare Conference on November 29 in New York City. Jeff Mirviss, senior vice president &...

Boston Scientific (NYSE: BSX) today announced results from the first clinical trial evaluating the performance of the HeartLogic™ Heart Failure Diagnostic Service to predict impending heart...

Boston Scientific (NYSE: BSX) has acquired the gynecology and urology portfolio of Distal Access, LLC, a Salt Lake City based company that designs minimally invasive medical devices. The portfolio...

MARLBOROUGH, Mass., (Nov. 8, 2016) – Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the Dakota™ Nitinol Stone Retrieval Device with OpenSure™...

Boston Scientific Corporation (NYSE: BSX) today announced that its wholly owned merger subsidiary, Falcon Merger Corp., has extended its previously announced tender offer for all shares of...

Boston Scientific (NYSE: BSX) today announced the acquisition of the LumenR™ Tissue Retractor System from LumenR LLC, a privately held Newark, California based company. The LumenR Tissue...

Boston Scientific (NYSE: BSX) announced initial U.S. commercial performance results of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device today during a late-breaking clinical trial...

As part of the commitment to support health equity for all patients, Boston Scientific Corporation (NYSE: BSX) sponsored the PLATINUM Diversity study to evaluate the clinical outcomes of the...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Stifel 2016 Healthcare Conference on November 15 in New York City. Dan Brennan, executive vice president & chief...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.105 billion during the third quarter ended September 30, 2016, compared to the company's guidance range for the quarter of $2.035 to...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 25th Annual Credit Suisse Healthcare Conference on November 7, in Scottsdale, Arizona. Joe Fitzgerald, executive vice...

Boston Scientific (NYSE: BSX) today announced key data which will be presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Resolution 360™ Clip, a novel technology designed to improve hemostatic clipping by providing physicians controlled...

Marlborough, Mass. October 13, 2016) -- Boston Scientific Corporation (NYSE: BSX) today announced a worldwide call for submissions to the second annual Boston Scientific Connected Patient...

Boston Scientific Corporation (NYSE: BSX) announced today that Professor Ian Meredith AM will join the company as executive vice president and global chief medical officer in January 2017. In his...

Boston Scientific Corporation (NYSE: BSX) today announced that its wholly owned merger subsidiary, Falcon Merger Corp., has launched its previously announced tender offer for all shares of...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2016 on Wednesday, October...

Boston Scientific (NYSE: BSX) and EndoChoice Holdings, Inc. (NYSE: GI) today announced the companies have entered into a definitive agreement under which Boston Scientific has agreed to acquire...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology. The...

Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 13, in New York City. Mike Mahoney, chief executive officer, and Dan...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, in Boston. Mike Mahoney, chief executive officer, Dan Brennan,...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 36th Annual Canaccord Genuity Growth Conference on August 11 in Boston and the 2016 Wedbush PacGrow Healthcare...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's guidance range for the quarter of $2.010 to...

Addition of leading radiofrequency ablation company expands therapeutic options for patients with chronic pain

CEO Mike Mahoney welcomes Fujimori as a business leader with “significant insights on how large companies plan, execute and compete globally.”

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2016. Learn how to tune in.

Studies show that treatment is less costly and has lower hospital re-admissions

Accelerates momentum to bring differentiated value to patients and health care systems

Boston Scientific will participate in the healthcare conference on June 9, 2016. A live webcast and replay will be available.

Boston Scientific will participate in the healthcare investor conference on June 7, 2016. A live webcast and replay will be available.

Full-body MRI access expands spinal cord stimulation offering and brings customized therapy to more patients suffering from chronic pain

Key data to be presented include real-world outcomes with the with the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device in Europe

Late-breaker data presented at HRS scientific sessions is most extensive post-market study for S-ICD

New catheters and software enhancement expand capabilities of high-definition Rhythmia™ Mapping System

Boston Scientific will participate in the healthcare investor conference on May 12, 2016. A live webcast and replay will be available.

Boston Scientific (NYSE: BSX) today announced key data, including one late-breaking clinical trial, that will be featured at the 37th Annual Scientific Sessions of the Heart Rhythm Society (HRS)...